CEO Interview: Ric Schumacher Pressure Bioscience (PBIO).
https://youtu.be/a8d1bawmMQk
RELATED: Adding Pressure BioSciences (PBIO) $0.80 to Watch...
Pressure BioSciences (PBIO) Receives $1.5M Contract for UltraShear Nanoemulsified CBD.
CBD Supply MD, a Leading Maryland-Based CBD Retailer, to Introduce PBIO's UltraShear Processed, Best-in-Class Nanoemulsified CBD Products Across the Multi-State Mid-Atlantic Region
Hepion (HEPA) Back in the Spotlight, Gains 230% in May.
Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of...
Video: New Topical Drug Delivery System, NeuroDirect™
Must Watch Video. Topical Application to Improve Delivery of FDA-Approved Drugs.
https://youtu.be/2CGT7P9QEvo
Can...
Topical PTSD Drug Poised for Human Trials.
In a press release issued on February 15, Psycheceutical Bioscience (BWVI), in partnership with iNGENū, a contract research organization in the cannabinoid...
Adding Psycheceutical Bioscience (BWVI) $0.14 to Watch List. Ketamine.
Above: Lamar Odom and Psychedelic Spokesman Mike Zappy Zapolin
We're Calling a Sector Bottom, and Psycheceutical (BWVI) as Our...
Pivotal Clinical Trials: Frequently Asked Questions (Sofpromed).
What is a pivotal clinical trial?
A pivotal clinical trial is a clinical study seeking...
Adding Cardiol Therapeutics (CRDL) $0.59 to Watch List.
Adding to 2023 Biotech Stock Review Watch List. We Think This One Has Legs.
Starting Due Diligence...
Is ATAI Live Sciences (ATAI) $2.00, Finally Turning?
After dropping 94% from post IPO high from $19.45, a loss exceeding $3 billion and change, ATAI is in the early stages of recovery (in...
Latest article
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
